Carregant...
Survival in melanoma brain metastases in the era of novel systemic therapies
BACKGROUND: Melanoma brain metastases (MBMs) have historically poor overall survival (OS). Recently introduced systemic anticancer therapies (SACTs), namely targeted therapies such as BRAF inhibitors and immunotherapy, to control advanced disease have shown improved survival. Today, increasingly agg...
Guardat en:
| Publicat a: | Neurooncol Adv |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7764504/ https://ncbi.nlm.nih.gov/pubmed/33392503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa144 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|